Session

Management of recurrent prostate cancer

Poster Session 44

  • Location:
    Room 14b (ICM, Level 1)
  • Chairs:
     A. Bjartell, Malmö (SE)
     A. Ponholzer, Vienna (AT)
     J. Rubio Briones, Valencia (ES)
  • Aims and objectives of this session

    Managing PSA recurrence after radical treatment remains one of the more difficult challenges in modern urology. That implies early identification
    and correct prognostication of individual risk. This session will present the latest update on the topic.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 544
Long-term impact of adjuvant versus early salvage radiation therapy on clinical recurrence in pT3N0 prostate cancer patients treated with radical prostatectomy: Results of a multi-institutional analysis

By: Fossati N.1, Karnes J.2, Morlacco A.3, Moschini M.1, Boorjian S.2, Seisen T.3, Bossi A.3, Cozzarini C.4, Fiorino C.4, Noris Chiorda B.4, Gandaglia G.1, Tosco L.5, De Ridder D.5, Joniau S.5, Goldner G.6, Shariat S.7, Hinkelbein W.8, Haustermans K.9, Tombal B.10, Montorsi F.1, Van Poppel H.5, Wiegel T.11, Briganti A.1

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Oncology/Unit of Urology; URI, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, United States of America, 3Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, 4IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 5University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 6Medical University of Vienna, Dept. of Radio oncology, Vienna, Austria, 7Medical University of Vienna, Dept. of Urology, Vienna, Austria, 8Charitè Universita¨tsmedizin, Campus Benjamin Franklin, Dept. of Radiation Oncology, Berlin, Germany, 9University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 10Universite´ Catholique De Louvain, Dept. of Urology, Brussels, Belgium, 11University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany

545
Early salvage radiotherapy gives favorable results in unfavorable prostate cancer patient subgroups

By: Wiegel T.1, Bartkowiak D.1, Bottke D.1, Siegmann A.2, Böhmer D.2, Budach V.2

Institutes: 1University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 2University Hospital Berlin, Dept. of Radiation Oncology, Berlin, Germany

546
Patterns of recurrence and long-term cancer-specific mortality of prostate cancer patients treated with salvage radical prostatectomy for radio-recurrent prostate cancer

By: Gandaglia G.1, Fossati N.2, Suardi N.2, Gallina A.2, Colombo R.2, Bertini R.2, Dehò F.2, Scattoni V.2, Stabile A.2, Cozzarini C.3, Rigatti P.4, Montorsi F.2, Briganti A.2

Institutes: 1Irccs Ospedale San Raffaele; Uri, Dept. of Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Oncology/Unit of Urology; URI, Milan, Italy, 3IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 4Advanced Urotechnology Center, Istituto Auxologico Italiano, Dept. of Urology, Milan, Italy

547
Clinical utility of PET-PSMA in decision-making for prostate cancer patients: Preliminary analysis of 42 consecutive patients

By: Albisinni S.1, Artigas C.2, Aoun F.1, Biaou I.1, Limani K.1, Hawaux E.1, Peltier A.1, Flamen P.2, Van Velthoven R.1

Institutes: 1Institut Jules Bordet, Dept. of Urology, Brussels, Belgium, 2Institut Jules Bordet, Dept. of Nuclear Medicine, Brussels, Belgium

548
68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment

By: Van Leeuwen P.J.1, Emmett L.2, Hruby G.3, Kneebone A.3, Stricker P.1

Institutes: 1St Vincent’s Prostate Cancer Centre, Dept. of Urology, Sydney, Australia, 2St Vincent’s Public Hospital, Dept. of Diagnostic Imaging, Sydney, Australia, 3Northern Sydney Cancer Centre, Royal North Shore Hospital, Dept. of Radiation Oncology, Sydney, Australia

549
Results of a prospective phase I/II randomized trial of peptide-specific vaccination in HLA-A*0201 positive prostate carcinoma patients with biochemical recurrence after radical prostatectomy

By: Bedke J.1, Gouttefangeas C.2, Feyerabend S.1, Hennenlotter J.1, Avilés Escobar C.M.1, Laske K.2, Widenmeyer M.2, Griesemann H.2, Stevanovic S.2, Rammensee H-G.2, Stenzl A.1

Institutes: 1University of Tübingen, Dept. of Urology, Tübingen, Germany, 2University of Tübingen, Dept. of Immunology, Tübingen, Germany

550
Oncologic outcomes and biochemical predictors following salvage lymph node dissection for prostate cancer

By: Zattoni F.1, Nehra A.1, Lowe V.2, Rangel L.1, Mynderse L.1, Kwon E.1, Karnes J.1

Institutes: 1Mayo Clinic, Dept. of Urology, Rochester, United States of America, 2Mayo Clinic, Dept. of Radiology, Rochester, United States of America

551
Feasibility of 111In-PSMA-guided surgery for treatment of nodal prostate cancer relapse

By: Schaal K.1, Stoykow C.2, Mix M.2, Bartholomä M.2, Drendel V.3, Mäcke H.2, Gourni E.2, Wetterauer U.1, Schultze-Seemann W.1, Meyer P.2, Jilg C.A.1

Institutes: 1University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, 2University Medical Center Freiburg, Dept. of Nuclear Medicine, Freiburg, Germany, 3University Medical Center Freiburg, Dept. of Pathology, Freiburg, Germany

552
Predicting the 5-year risk of biochemical relapse after post-prostatectomy radiotherapy in ≥pT2 patients with a comprehensive radiobiological model

By: Fiorino C.1, Broggi S.1, Fossati N.2, Cozzarini C.3, Goldner G.4, Wiegel T.5, Hinkelbein W.6, Karnes J.7, Haustermans K.8, Joniau S.9, De Ridder D.9, Shariat S.10, Montorsi F.2, Van Poppel H.9, Di Muzio N.3, Calandrino R.1, Briganti A.2

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 3IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, 4Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, 5University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, 6Charite´ Universita¨tsmedizin, Campus Benjamin Franklin, Dept. of Radiation Oncology, Berlin, Germany, 7Mayo Clinic, Dept. of Urology, Rochester, United States of America, 8University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, 9University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, 10Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria

553
Salvage tomotherapy choline PET/CT guided for prostate cancer lymph nodal recurrence

By: Fodor A.1, Genoveffa B.1, Fiorino C.2, Picchio M.3, Busnardo E.3, Kirienko M.4, Incerti E.3, Cozzarini C.1, Dell’Oca I.1, Mangili P.2, Pasetti M.1, Calandrino R.2, Gianolli L.3, Di Muzio N.G.1

Institutes: 1San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, 2San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, 3San Raffaele Scientific Institute, Dept. of Nuclear Medicine, Milan, Italy, 4University Milano-Bicocca, Dept. of Nuclear Medicine, Milan, Italy

554
Does salvage lymphadenectomy for biochemical progression following radical prostatectomy and additional radiotherapy has an impact on overall survival? Initial results from a case-control study

By: Jilg C.A.1, Tennstedt P.2, Heinzer H.2, Wetterauer U.1, Grosu A.3, Budaeus L.2, Schultze-Seemann W.1, Steuber T.2

Institutes: 1University Medical Center Freiburg, Dept. of Urology, Freiburg, Germany, 2Martini-Clinic, University Hospital Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 3University Medical Center Freiburg, Dept. of Radiation Oncology, Freiburg, Germany

555
Long-term oncological outcomes of salvage cryotherapy for radio-recurrent prostate cancer

By: Siddiqui K.1, Billia M.1, Violette P.2, Arifin A.1, Tran K.1, Chin J.1

Institutes: 1University of Western Ontario, Dept. of Urology, London, Canada, 2Woodstock Hospital, Dept. of Urology, Woodstock, Canada

556
A prospective phase II clinical trial of salvage whole gland high intensity focused ultrasound for radio-recurrent prostate: Intermediate term results

By: Siddiqui K.1, Billia M.1, Violette P.2, Chin J.2

Institutes: 1University of Western Ontario, Dept. of Urology, London, Canada, 2Woodstock Hospital, Dept. of Urology, London, Canada

Summary and context
 J. Rubio Briones, Valencia (ES)